Stock 6622 ZHAOKE OPHTHALMOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Zhaoke Ophthalmology Limited Share Price

Equities

6622

KYG989M51017

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
1.51 HKD -1.95% Intraday chart for Zhaoke Ophthalmology Limited -2.58% -61.77%
04-08 Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director CI
03-27 Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 18.75M 2.59M 20.26M 207M Sales 2024 * 29.14M 4.02M 31.48M 322M Capitalization 763M 105M 825M 8.44B
Net income 2023 * - Net income 2024 * - EV / Sales 2023 105 x
Net cash position 2023 * 1.2B 166M 1.3B 13.27B Net cash position 2024 * 1.06B 146M 1.15B 11.72B EV / Sales 2024 * -10.2 x
P/E ratio 2023
-5.06 x
P/E ratio 2024 *
-
Employees 313
Yield 2023 *
-
Yield 2024 *
-
Free-Float 62.6%
More Fundamentals * Assessed data

Chart Zhaoke Ophthalmology Limited

Dynamic Chart

Latest news about Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director CI
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea MT
Zhaoke Ophthalmology's Investigational New Drug Applications for Pupil-Modulating Eye Drops Given Green Light by Chinese Regulator MT
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia CI
Zhaoke Ophthalmology Limited Announces Executive Changes CI
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan MT
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study MT
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China CI
Zhaoke Ophthalmology Enlists Patients for 2 Drug Trials; Will Refile NDA for Eye Gel MT
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel CI
Zhaoke Ophthalmology's Loss Widens in H1 MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhaoke Ophthalmology Concludes Phase III Trial of Myopia Medication MT
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial CI
More news

Press releases Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology's Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children AQ
Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children AQ
Zhaoke Ophthalmology Announces 2022 Interim Results AQ
Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002 AQ
Zhaoke Ophthalmology : Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdong Medical Products Administration PR
More press releases

Quotes and Performance

1 day-1.95%
1 week-2.58%
Current month-4.43%
1 month-3.21%
3 months-50.49%
6 months-62.53%
Current year-61.77%
More quotes

Highs and lows

1 week
1.49
Extreme 1.49
1.60
1 month
1.49
Extreme 1.49
1.65
Current year
1.49
Extreme 1.49
3.93
1 year
1.49
Extreme 1.49
4.50
3 years
1.49
Extreme 1.49
15.60
5 years
1.49
Extreme 1.49
15.60
10 years
1.49
Extreme 1.49
15.60
More quotes

Managers and Directors - Zhaoke Ophthalmology Limited

Managers TitleAgeSince
Xiao Yi Li CEO
 Chief Executive Officer 62 19/01/17
Lit-Fui Lau PSD
 President 62 31/05/16
Xin Yan Feng DFI
 Director of Finance/CFO 47 06/12/20
Members of the board TitleAgeSince
Hin Wing Wong BRD
 Director/Board Member 62 31/03/21
Yuk Lam Lo BRD
 Director/Board Member 76 31/03/21
Xiao Yi Li CEO
 Chief Executive Officer 62 19/01/17
More insiders

ETFs positioned on Zhaoke Ophthalmology Limited

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.01% 4 M€ -27.92%
More ETFs positioned on Zhaoke Ophthalmology Limited

Quotes

Date Price Change Volume
26/04/24 1.51 -1.95% 872,000
25/04/24 1.54 -1.28% 370,500
24/04/24 1.56 -1.89% 418,500
23/04/24 1.59 +2.58% 251,000
22/04/24 1.55 0.00% 235,500

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes

Company Profile

Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company’s products include innovative drugs and generic drugs. The Company ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.
Sector
Pharmaceuticals
Calendar
20/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.398 CNY
Average target price
7.1 CNY
Spread / Average Target
+407.99%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHAOKE OPHTHALMOLOGY LIMITED Stock Zhaoke Ophthalmology Limited
-61.77% 105M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6622 Stock